Table of Contents
- Trial overview
- Anorexia nervosa study
- Prodromal Parkinson’s disease study
- Main outcomes and what they mean
- Who can participate
- Study phases and status
Trial overview
The available trials of 3-AMINO-4-[2-[[METHYL((111C)METHYL)AMINO]METHYL]PHENYL]SULFANYLBENZONITRILE are imaging studies that explore serotonin-related brain activity in specific patient groups.[1][2]
These studies are not testing treatment for symptoms; instead, they are using PET imaging to compare brain signals between patient groups and control groups.[1][2]
Anorexia nervosa study
The first trial, NCT05155280, is a Phase 3 interventional study in people with anorexia nervosa and control subjects.[1]
Its goal is to evaluate differences in serotonergic transmission, which means how the serotonin system works in the brain, especially in networks involved in food intake and the striatum, a brain area that helps control behavior and movement.[1]
The study title also shows that it looks at gaze control and multimodal brain imaging, which means it uses more than one imaging method to study brain function.[1]
The main outcome is BPND, or non-displaceable binding potential, which is a PET scan measure of how strongly the tracer binds in the brain.[1]
This trial enrolled 75 participants and is listed as completed.[1]
Prodromal Parkinson’s disease study
The second trial, 2024-516610-38-00, is a Phase 4 interventional study called SerIAL-PD.[2]
It studies people with prodromal Parkinson’s disease, which means the early phase before clear Parkinson’s symptoms appear, and it focuses on people with SNCA gene mutations.[2]
The study compares participants with SNCA mutations who do not yet have Parkinson’s disease to healthy controls without the mutation.[2]
The trial uses the radiotracers [11C]DASB and [11C]SB207145 to measure binding to the serotonin transporter SERT and the 5-HT4 receptor, both of which are parts of the serotonin system.[2]
The primary outcome is to determine PET-binding potential and compare it between the study groups.[2]
This trial plans to enroll 50 participants and is listed as authorised.[2]
Main outcomes and what they mean
Both trials use PET imaging, which is a scan that shows where a tracer goes in the body and how much it binds to its target.[1][2]
In the anorexia nervosa study, the outcome is BPND, while in the Parkinson’s study, the outcome is PET-binding potential for the tracers [11C]DASB and [11C]SB207145.[1][2]
These measures help researchers see whether serotonin-related brain signals are different in patients compared with control groups.[1][2]
Who can participate
Participation is limited to the groups named in the trial records.[1][2]
The anorexia nervosa study includes people with anorexia nervosa and control subjects.[1]
The Parkinson’s study includes people with SNCA mutations who do not yet have Parkinson’s disease, as well as healthy controls.[2]
Study phases and status
The anorexia nervosa trial is Phase 3 and has been completed.[1]
The Parkinson’s study is Phase 4 and is authorised.[2]
Both studies are interventional, meaning the research team gives the study tracer as part of the protocol and measures the brain imaging results.[1][2]
